# A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

> **NCT06017258** · PHASE1 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 15 (estimated)

## Conditions studied

- Refractory Acute Myeloid Leukemia
- Relapsed Acute Myeloid Leukemia
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory

## Interventions

- **BIOLOGICAL:** CD371-specific/YSNVz/I-18 CAR T cells

## Key facts

- **NCT ID:** NCT06017258
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-22
- **Primary completion:** 2026-08-22
- **Final completion:** 2026-08-22
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06017258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06017258, "A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06017258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*